Molecular mechanisms involved in the reciprocal regulation of cyclooxygenase and nitric oxide synthase enzymes

被引:90
作者
Cuzzocrea, S.
Salvemini, D.
机构
[1] St Louis Univ, Sch Med, Div Pulm, Dept Internal Med Crit Care & Sleep Med, St Louis, MO 63110 USA
[2] Univ Messina, Dept Clin & Expt Med & Pharmacol, Messina, Italy
[3] IRCCS Ctr Neurol Bonino Pulejo, Inst Shelter & Care Sci Character, Messina, Italy
关键词
nitric oxide; prostaglandins; cyclooxygenase; inflammation;
D O I
10.1038/sj.ki.5002058
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The nitric oxide ( NO) and cyclooxygenase ( COX) pathways share a number of similarities. NO is the mediator generated from the NO synthase ( NOS) pathway and COX converts arachidonic acid to prostaglandins ( PGs), prostacyclin, and thromboxane A(2). Two major forms of NOS and COX have been identified to date. The constitutive isoforms of these enzymes play an important role in the regulation of several physiological states. On the other hand, in an inflammatory setting, the inducible isoforms of these enzymes are induced in a variety of cells resulting in the production of large amounts NO and PGs, which play pathological roles in several disease states. An important link between the NOS and COX pathways was made by our group when we demonstrated that NO activates the COX enzymes, an event leading to overt production of PGs, suggesting that COX enzymes represent important endogenous 'receptor' targets for modulating the multifaceted roles of NO. More importantly, mechanistic studies of how NO activates the COX enzymes have been undertaken and additional pathways through which NO modulates PG production unraveled. The purpose of this article is to cover the advances, which have occurred over the years and in particular to summarize experimental data that outline how the discovery that NO modulates PG production has impacted and extended our understanding of these two systems in physiopathological events.
引用
收藏
页码:290 / 297
页数:8
相关论文
共 97 条
[1]   Kinetics of peroxynitrite reaction with amino acids and human serum albumin [J].
Alvarez, B ;
Ferrer-Sueta, G ;
Freeman, BA ;
Radi, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (02) :842-848
[2]  
ANGGARD EE, 1991, EUR HEART J, V12, P5
[3]  
BAILEY JM, 1985, J LIPID RES, V26, P54
[4]   Chronic inhibition of NO synthase enhances the production of prostacyclin in coronary arteries through upregulation of the cyclooxygenase type 1 isoform [J].
Beverelli, F ;
Bea, ML ;
Puybasset, L ;
Giudicelli, JF ;
Berdeaux, A .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1997, 11 (03) :252-259
[5]   Cyclooxygenase-2 inhibitors: Is there an association with coronary or renal events? [J].
Richard J. Bing .
Current Atherosclerosis Reports, 2003, 5 (2) :114-117
[6]   Activation of nuclear factor kappa B by beta-amyloid peptides and interferon-gamma in murine microglia [J].
Bonaiuto, C ;
McDonald, PP ;
Rossi, F ;
Cassatella, MA .
JOURNAL OF NEUROIMMUNOLOGY, 1997, 77 (01) :51-56
[7]   IL-1-induced iNOS expression in human astrocytes via NF-kappa B [J].
Chao, CC ;
Lokensgard, JR ;
Sheng, WS ;
Hu, SX ;
Peterson, PK .
NEUROREPORT, 1997, 8 (14) :3163-3166
[8]   GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury [J].
Chatterjee, PK ;
Patel, NSA ;
Sivarajah, A ;
Kvale, EO ;
Dugo, L ;
Cuzzocrea, S ;
Brown, PAJ ;
Stewart, KN ;
Mota-Filipe, H ;
Britti, D ;
Yaqoob, MM ;
Thiemermann, C .
KIDNEY INTERNATIONAL, 2003, 63 (03) :853-865
[9]   Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury [J].
Chatterjee, PK ;
Patel, NSA ;
Kvale, EO ;
Cuzzocrea, S ;
Brown, PAJ ;
Stewart, KN ;
Mota-Filipe, H ;
Thiemermann, C .
KIDNEY INTERNATIONAL, 2002, 61 (03) :862-871
[10]   Effect of inhibition of nitric oxide synthase on renal cyclooxygenase in the diabetic rat [J].
Chen, Yu-Jung ;
Li, Jing ;
Quilley, John .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 541 (1-2) :80-86